

Specialised Rheumatology (Adult) Quality Dashboard 2020/21



Indicator Reference Number	Domain	Theme	Measure	Rationale	Indicator Name/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
RHEUM01a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time (in days) from receipt of initial GP referral to first attended dedicated specialist non urgent OPD appointment for patients with connective tissue disease and/or vasculitis	Total time in days (i.e. total sum of time in days from receipt of new GP referral to first attended appointment)	Total number of new GP referrals for patients with suspected or confirmed connective tissue disease and/or vasculitis seen within the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM01b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time (in days) from receipt of secondary care referral to first attended dedicated specialist non urgent OPD appointment for patients with connective tissue disease and/or vasculitis	Total time in days (i.e. total sum of time in days from receipt of secondary care referral to first attended appointment)	Total number of secondary care referrals for patients with suspected or confirmed connective tissue disease and/or vasculitis seen within the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM01c	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time (in days) from receipt of initial GP referral to first attended dedicated specialist non urgent OPD for patients with inherited connective tissue diseases and/or metabolic bone	Total time in days i.e. total sum of time in days from receipt of new GP referral to first attended appointment)	Total number of new GP referrals for patients with suspected or confirmed inherited connective tissue diseases and/or metabolic bone seen within the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM01d	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Timely appointments		Mean time (in days) from receipt of secondary care referral to first attended dedicated specialist non urgent OPD for patients with inherited connective tissue diseases and/or metabolic bone	Total time in days (i.e. total sum of time in days from receipt of secondary care referral to first attended appointment)	Total number of secondary care referrals for patients with suspected or confirmed inherited connective tissue diseases and/or metabolic bone seen within the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Lower is better	For patients who have postponed own appointment include date from registering referral to first offered appointment	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM02a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Day case specialised service specification activity		Proportion of rheumatology day case treatments that fall within the specialised service specification for the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	From denominator, total number of specialised rheumatology day case treatments with the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	Total number of rheumatology day case treatments performed in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data			Numerator note: number of specialised rheumatology patients with relevant diagnoses using coding for episode	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM02b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Process	Inpatient specialised service specification activity		Proportion of rheumatology inpatients admitted that fall within the specialised service specification for the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	From denominator, total number of rheumatology inpatients admitted with the following diagnoses: A) SLE B) Systemic sclerosis C) Myositis D) Vasculitis E) Primary Sjogren's Syndrome F) Osteogenesis imperfecta	Total number of rheumatology inpatients admitted in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data			Numerator note: number of specialised rheumatology patients with relevant diagnoses using coding for episode	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM03	Domain 3: Helping people to recover from episodes of ill health or following injury	Process	Registry registration		Proportion of patients with SLE who received rituximab and are registered on BILAGBR (British Isles Lupus Assessment Group Biologics Registry)	From denominator, total number of patients who received rituximab and are registered on BILAGBR	Number of patients with SLE who received rituximab in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better	Number of patients may not equal number of infusions, as a patient may have received two pulses, as part of a course of rituximab	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM04	Domain 3: Helping people to recover from episodes of ill health or following injury	Process	Registry registration		Proportion of patients with ANCA-associated vasculitis who received rituximab and are registered on UKIVAS	From denominator, total number of patients who received rituximab and are registered on UKIVAS	Number of patients with ANCA-associated vasculitis who received rituximab in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data		Higher is better	Number of patients may not equal number of infusions, as a patient may have received two pulses, as part of a course of rituximab	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM07a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical Process	Patient participation in research studies		Proportion of all specialised rheumatology service patients seen in OPD who have participated in National Institute for Health Research (NIHR) Clinical Research Network Portfolio studies (Cross sectional)	From denominator, number of specialised rheumatology service patients who have participated in NIHR registered cross sectional research studies in the reporting period	Number of specialised service rheumatology patients seen in OPD in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data			Refers to patients who participate in a research study for one off visits to provide data/samples. A patient may participate in more than one research study but must only be counted once. Data for denominator should be specialised rheumatology patients attending dedicated clinics/MDTs. For the purposes of the quality dashboard, a specialised rheumatology patient is one with a rheumatology diagnosis that is included in the service specification for specialised rheumatology (adult) A13/5/a: 1. Autoimmune connective tissue diseases and vasculitis: e.g. SLE, systemic sclerosis, dermatomyositis, polymyositis, primary Sjogren's syndrome, ANCA associated vasculitis, polyarteritis nodosa, Takayasu's arteritis 2. Inherited connective tissue diseases: e.g. Ehlers Danlos syndrome (excluding type III), Marfan's syndrome, pseudoxanthoma elasticum 3. Complex metabolic bone syndromes: e.g. osteogenesis imperfecta, fibrous dysplasia, chondrodysplasia	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21

Specialised Rheumatology (Adult) Quality Dashboard 2020/21



Indicator Reference Number	Domain	Theme	Measure	Rationale	Indicator Name/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
RHEUM07b	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical Process	Patient participation in research studies		Proportion of all specialised rheumatology service patients seen in OPD who have participated in National Institute for Health Research (NIHR) Clinical Research Network Portfolio studies - Longitudinal (includes longitudinal observational studies and interventional studies)	From denominator, number of specialised rheumatology service patients who have participated in ongoing NIHR-registered longitudinal research studies in the reporting period	Number of specialised service rheumatology patients seen in OPD in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data			Refers to patients who are participating in a longitudinal study with two or more visits e.g. RCT, etc. A patient may participate in more than one research study but must only be counted once. Data for denominator should be specialised rheumatology patients attending dedicated clinics/MDTs. For the purposes of the quality dashboard, a specialised rheumatology patient is one with a rheumatology diagnosis that is included in the service specification for specialised rheumatology (adult) A13/5/a: 1. Autoimmune connective tissue diseases and vasculitis: e.g. SLE, systemic sclerosis, dermatomyositis, polymyositis, primary Sjogren's syndrome, ANCA associated vasculitis, polyarteritis nodosa, Takayasu's arteritis 2. Inherited connective tissue diseases: e.g. Ehlers Danlos syndrome (excluding type III), Marfan's syndrome, pseudoxanthoma elasticum 3. Complex metabolic bone syndromes: e.g. osteogenesis imperfecta, fibrous dysplasia, chondrodysplasia	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
RHEUM09	Domain 3: Helping people to recover from episodes of ill health or following injury	Clinical Process	Registry registration		Proportion of patients with inflammatory myositis who received rituximab and are registered on MYOACT/MYOPROSP (Myositis Disease Activity/Myositis Prospective Registry)	From denominator, total number of patients who received rituximab and are registered on MYOACT/MYOPROSP	Number of patients with inflammatory myositis who received rituximab (within the reporting period)	Quarterly	Quarterly	Provider submitted data	Provider submitted data	Higher is better	Number of patients may not equal number of infusions, as a patient may have received two pulses as part of a course of rituximab	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21	
RHEUM10	Domain 3: Helping people to recover from episodes of ill health or following injury	Clinical Process	Registry registration		Proportion of patients with SLE who received belimumab and are registered on BILAGBR (British Isles Lupus Assessment Group Biologics Registry)	From denominator, total number of patients who received belimumab and are registered on BILAGBR	Number of patients with SLE who received belimumab (within the reporting period)	Quarterly	Quarterly	Provider submitted data	Provider submitted data	Higher is better	Number of patients may not equal number of infusions, as a patient may have received three or four pulses, as part of a their ongoing treatment with belimumab	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21	